Alerta

ENZYME MEDIATOR FUNCTIONALIZED POLYMERS FOR USE WITH ANALYTE SENSORS

Resumen de: US20260209815A1

0000 Embodiments of the invention provide amperometric analyte sensors having elements selected to optimize enzymatic activities associated with such sensors including polymers functionalized with enzymatic mediators as well as methods for making and using such sensors. While embodiments of the invention can be used in a variety of contexts, typical embodiments of the invention include glucose or ketone sensors used in the management of diabetes.

Species-Specific Tissue Culture Medium for the Propagation of Cells

Resumen de: US20260209710A1

0000 A cell culture medium is disclosed. The cell culture medium comprises: a species-specific cell culture medium comprising: bFGF of the species, PDGF-BB of the species, and EGF of the species; and serum of the species. Further disclosed is a canine cell culture medium comprising: canine bFGF, canine PDGF-BB, and canine EGF; and canine serum. A composition is described comprising: a medium comprising: basal medium, sodium bicarbonate, HEPES, L-glutamine, L-alanine, Insulin, hydrocortisone, progesterone, Asc-2-p, holo-transferrin; bFGF of the species, PDGF-BB of the species, and EGF of the species; and serum consistent with the cells of the species; MSC cells of the species. A method of producing exosomes is described, the method comprising: expanding mesenchymal stem cells and/or islet cells in culture, the culture and collecting exosomes released by the mesenchymal and/or adipose stem cells in culture.

REAL TIME MANAGEMENT OF DATA RELATING TO PHYSIOLOGICAL CONTROL OF GLUCOSE LEVELS

Resumen de: US20260211903A1

Integrated glucose monitoring systems, comprising a memory configured to store data relating to at least two glucose measurements of a user, a glucose safe range, and exogenous data. Wherein the at least two glucose measurements of the user are at different time points t1 and t2; a user interface comprising a display; and a processor comprising computer-executable instructions. Wherein the computer-executable instructions determine a rate of change based on the at least two glucose measurements of the user; determine, based on the at least two glucose measurements of the user and the determined rate of change, a projected glucose level at a future time t3; and provide an alarm at the user interface if, based on at least one point of exogenous data, the projected glucose level at future time t3 is outside of the glucose safe range.

ANALYTE SENSORS AND SENSING METHODS FOR DETECTING INHIBITORS OF DIAPHORASE

Resumen de: US20260207096A1

Analyte sensors featuring an enzyme system comprising diaphorase and a NAD-dependent dehydrogenase may be utilized to detect inhibitors of diaphorase, provided that the transfer of electrons to a working electrode is rate-limiting with respect to the diaphorase. Such analyte sensors may comprise a sensor tail comprising at least a first working electrode, a first active area disposed upon a surface of the first working electrode, and an analyte-permeable membrane overcoating at least the first active area. The enzyme system comprises NAD, reduced NAD, or any combination thereof; a NAD-dependent dehydrogenase, such as NAD-dependent glucose dehydrogenase; and diaphorase. Inhibitors of diaphorase that may be detected include, for example, warfarin, dicoumarol, and similar compounds. A second active area may be present to facilitate detection of an analyte differing from the inhibitor of diaphorase.

AUTOMATED INSULIN DELIVERY DEVICE AND METHODS ASSOCIATED THEREOF

Resumen de: WO2026154477A1

The present disclosure is directed to embodiments for an automated insulin delivery (AID) device which includes, inter alia, a housing including an adhesive tape configured, to adhere the housing to the skin of a user via. an adhesive tape. The housing houses at least an insulin pump including a single lumen cannula, a glucose sensor including a sensor probe, a processor, an insertion assembly for inserting the single lumen cannula, and the sensor probe within subcutaneous tissue, and an automated-insulin-delivery algorithm (AIDA). The sensor probe at least partially resides within the single lumen cannula, and the AIDA is configured as computer instructions operating on the processor causing the processor to automatically control insulin delivery by the insulin pump according to glucose levels from subcutaneous tissue based on signals received from the glucose sensor.

METHODS FOR GENERATING INSULIN-SECRETING PANCREATIC ISLET-LIKE CELLS

Resumen de: WO2026155698A1

Various embodiments of the present invention relate generally to stem cell biology, developmental biology, and regenerative medicine. More particularly, various embodiments relate to methods, compositions, culture systems, and kits for directing the differentiation of human pluripotent stem cells, including human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs), into pancreatic lineage cells such as functional islet-like cells. In further embodiments, the invention relates to populations of pancreatic lineage cells produced by the disclosed methods, as well as their use in disease modelling, drug screening, and cell replacement therapies for metabolic disorders such as diabetes.

A NON-INVASIVE DIAGNOSIS SYSTEM

Resumen de: WO2026154262A1

A non-invasive diagnosis system, which comprises: a device for collecting a breath sample from a user, which comprises a mouthpiece; a spectrometer for measuring Volatile Organic Compounds, VOCs, in the breath sample; and a processor, wherein the processor is configured to analyse the measured VOCs using one or more machine learning models for classifying the user, based on one or more combinations of the measured VOCs, as healthy, prediabetic, Type 1 or Type 2 diabetes mellitus.

NON-HEMATOPOIETIC CELLS FROM PERIPHERAL BLOOD AND USES THEREOF

Resumen de: WO2026156219A1

Provided are methods of deriving a cell population containing pericytes and endothelial progenitor cells from a peripheral blood sample containing non-hematopoielic cells, which rely on culture media supplemented with serum and in certain embodiments also lacking epidermal growth factor, methods of editing mammalian peripheral blood-derived pericytes, and cells generated these methods. Also provided are serum-free defined cell media containing PDGF-beta; VEGF-C; a Notch ligand; a fibroblast growth factor; a TGF-beta superfamily member; an insulin agonist; transferrin; a hepatocyte growth factor; and a Wnt antagonist. The serum-free defined cell media can be used to derive and/or culture pericytes.

COMPONENT FOR CULTURE MEDIUM

Resumen de: WO2026155233A1

Provided is a culture medium for culturing cells containing specific components. Provided is a culture medium comprising at least one component selected from a group consisting of (1) halcinonides, (2) ALK4/7 inhibitor or TGFβ receptor type 1 kinase inhibitor, (3) BRD7/9 dual degradation factor or BRD7/9 binding molecule (degradation factor), (4) LATS1/2 inhibitor, PKA inhibitor, or AKT1 inhibitor, (5) CK1/2 inhibitor, insulin receptor Tyr kinase inhibitor, PKA inhibitor, or PKC inhibitor or adenosine kinase inhibitor, (6) E-selectin inhibitor, VCAM1 inhibitor, or ICAM1 inhibitor, and (7) LATS1 inhibitor + LATS2 inhibitor.

WEARABLE DEVICE FOR CONTINUOUS GLUCOSE MONITORING

Resumen de: US20260207087A1

0000 Disclosed herein is a wearable device for continuous glucose monitoring including a housing having a top surface opposite a bottom surface. A portion of the top surface is moveable relative to the bottom surface. The bottom surface has an opening and is configured to secure directly to skin. A puck assembly has a sensor, a wire coupled to the sensor, and a plurality of contacts. A rigid member is configured to move relative to the bottom surface. An engagement member is configured to rotate about an axis. A cutting element is coupled to the engagement member. Displacement of the movable portion of the top surface moves the rigid member into contact with the engagement member. The cutting element rotates through the opening to form an incision in the skin then to a locked position within the housing. The sensor and the wire advance through the opening and into the incision.

COMBINATION OF CULTURE MEDIUM COMPONENTS

Resumen de: WO2026155234A1

The present disclosure provides a culture medium for cell culturing, the culture medium containing a combination of specific components. The present disclosure provides a culture medium which contains a combination of components selected from the group consisting of: (1) a halcinonide component; (2) an ALK4/7 inhibitor or a TGFβ receptor type-1 kinase inhibitor; (3) a BRD7/9 double degradation factor or a BRD7/9 binding molecule (degradation factor); (4) an LATS1/2 inhibitor, a PKA inhibitor, or an AKT1 inhibitor; (5) a CK1/2 inhibitor, an insulin receptor inhibitor, a Tyr kinase inhibitor, a PKA inhibitor or a PKC inhibitor, or an adenosine kinase inhibitor; (6) an E-selectin inhibitor, a VCAM1 inhibitor, or an ICAM1 inhibitor; and (7) an LATS1 inhibitor + an LATS2 inhibitor.

System and Method for Analysis of Endoscopic Imaging

Resumen de: US20260207176A1

0000 A system and method for artificial intelligence (AI)-assisted medical diagnostics. A real-time endoscopic ultrasound (EUS) video stream of a patient's organ, such as the pancreas, is received at a computing device. The EUS video stream comprises a plurality of imaging modalities, including at least grey-scale data and elastography data representing tissue stiffness. One or more processors execute an AI model, which processes the video stream to identify, segment, and characterize a region of interest. A visual output is generated for display on a user interface in real-time, the output comprising the EUS video stream with a graphical overlay that includes a visual indicator delineating the segmented region and a classification label corresponding to the characterization, thereby providing real-time clinical decision support.

COMPUTER IMPLEMENTED METHOD OF TRAINING A MACHINE LEARNING MODEL CONFIGURED FOR PREDICTING A HYPOGLYCEMIC EVENT FOR A SUBJECT

Resumen de: WO2026154038A1

A computer implemented method of training a machine learning model configured for predicting a hypoglycemic event for a subject is proposed, comprising: i. (126) receiving at least two time series of glucose sensor data, wherein each time series of glucose sensor data comprises a plurality of glucose measurements measured by a glucose monitoring device (112) configured for detecting glucose in a bodily fluid of the subject, wherein a first time series of the two time series of glucose sensor data is measured at least during and/or after being exposed to a first predefined program of glycemic stimuli, and wherein a second time series of the two time series of glucose sensor data is measured at least during and/or after being exposed to a second predefined program of glycemic stimuli, wherein the second predefined program of glycemic stimuli is different from the first predefined program of glycemic stimuli; ii. (128) forming a first training dataset using the first time series and forming a second training dataset using the second time series; iii. (130) training the machine learning model with the first training dataset and the second training dataset.

REFRIGERATION CUP FOR INSULIN PEN

Resumen de: WO2026152526A1

Provided is a refrigeration cup for an insulin pen in which an insulin cartridge is arranged. The refrigeration cup comprises a refrigeration assembly, a cold conduction cylinder (500), a cup lid (100), and a cup body (200). The refrigeration assembly comprises a semiconductor refrigeration sheet (401), a heat conduction member (402), and a heat dissipation fan (403). The semiconductor refrigeration sheet (401) comprises a cold end and a hot end, and the hot end is attached to the heat conduction member (402). The cold conduction cylinder (500) comprises a sealed end (501) and an open end (502), and the cold end is attached to the sealed end (501). The cup lid (100) is suitable for accommodating the refrigeration assembly. The sealed end (501) is relatively fixedly connected to the semiconductor refrigeration sheet (401) and/or the cup lid (100). The cup body (200) comprises a cup wall (201) and a heat preservation cavity (202) defined by the cup wall (201). The open end (502) extends into the heat preservation cavity (202), and the cup lid (100) detachably seals the heat preservation cavity (202). The cold conduction cylinder (500) or the heat preservation cavity (202) defines an accommodating space capable of accommodating at most one or two insulin pens. The accommodating space is also suitable for accommodating the insulin cartridge. The diameter of the accommodating space ranges from 20 mm to 50 mm. By means of limiting the size of the cold conduction cylinder (500), por

INTERFERENCE REJECTION MEMBRANES COMPRISING CROSSLINKED POLY(VINYL ALCOHOL) MATRICES FOR IMPLANTABLE GLUCOSE SENSORS

Resumen de: US20260207098A1

0000 Embodiments of the invention provide amperometric analyte sensors having optimized elements such as interference rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; an interference rejection membrane disposed on an electroactive surface of the working electrode, wherein the interference rejection membrane comprises poly(vinyl alcohol) (PVA) polymers crosslinked by an acid crosslinker, wherein the crosslinker is a dicarboxylic acid type monomer or a polymer comprising a carboxylic acid group; and an analyte sensing layer. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.

SYSTEMS, DEVICES AND METHODS FOR PREDICTING DIABETIC STATUS USING VOICE

Resumen de: WO2024250121A2

Provided are computer-implemented methods, systems and devices for generating a type-II (T2DM) diabetic status prediction, including: extracting voice biomarker feature values from the voice sample for predetermined voice biomarker features; determining the T2DM diabetic status prediction for the subject based on the biomarker feature values and the diabetic status prediction model; and outputting the T2DM diabetic status prediction for the subject. Provided are computer-implemented methods, systems and devices for generating a diabetic status model for predicting a T2DM diabetic status, including: diabetic status labels identifying a corresponding diabetic status for training subjects; and voice samples collected from the training subjects at different time points, each of the voice samples associated with a corresponding diabetic status label; determining voice feature values for corresponding voice features for each of the voice samples in the voice samples; and generating the diabetic status model based on the voice samples and the voice feature values.

COMPOSITION COMPRISING (A) A DUAL AGENT ACTING AS A 5-HT2A RECEPTOR ANTAGONIST AND CYP2D6 INHIBITOR AND (B) AN NMDA RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF DISEASES INVOLVING GLUCOSE

Resumen de: WO2018039642A1

Compounds of formula I, (I) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N- oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: (IIa) (IIb) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.

INSULIN FRAGMENT TAG AND PHARMACEUTICAL COMPOSITION

Resumen de: US20260201010A1

The present invention addresses the problem of providing a polypeptide tag that is capable of delivering peptides or polypeptides to neurons. The problem is solved by an insulin fragment tag for delivering interested molecules to neurons, the insulin fragment tag comprising a polypeptide including an amino acid sequence that has at least 90% identity with the amino acid sequence of at least one chain selected from an insulin A-chain and an insulin B-chain, and the insulin fragment tag having binding capacity insulin receptors.

SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR CGM-BASED OGTT REPLACEMENT DIAGNOSIS TEST

Resumen de: US20260204418A1

0000 Embodiments relate to a database management system for efficient physiological diagnosis of a specified physiological disorder. The system includes a physical data store containing glucose measurement data and a representation for a classification of the glucose measurement data. The glucose measurement data is associated with controlled glycemic-response consumption activity, the representation being indication that a glucose measurement trace is associated of a specified physiological disorder or is indicative of the specified physiological disorder, or is a surrogate of an existing metabolic test, e.g. OGTT. A processor receives a new glucose measurement possibly associated with controlled glycemic-response consumption activity, and classifies the newly received glucose measurement trace with the representation based either on a disease- or test-specific classifier or based on a matched similarity metric, and ascribes a clinical recommendation or assessment based on the representation of the classified newly received glucose measurement trace.

METHOD OF DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MONOHORMONAL CELLS

Resumen de: US20260201339A1

0000 Compositions and methods are provided for generation of a population of monohormonal from human pluripotent cells. The method comprises sequentially exposing pluripotent stem cells to medium comprising CHIR99021 and Activin A; medium comprising Activin A; medium comprising FGF7; medium comprising retinoic acid, LDN193189, SANT1; medium comprising retinoic acid, LDN193189, SANT1, EGF and FGF2; and differentiation medium. A majority of cells in the population are monohormonal cells produce insulin, but not glucagon, somatostatin or ghrelin.

GLUCOSE MONITORING

Resumen de: US20260198807A1

0000 A light source is tuned to a range of wavelengths selected for relatively high absorption by glucose, while an optical sensor uses a complementary filter that selectively absorbs in the same spectrum. This optical channel, in combination with a separate, unfiltered reference optical channel, supports a calculation of glucose concentration in target tissue based on a ratiometric comparison of measured light intensities. In embodiments, quantum dots or other techniques can be used to tune the optical spectrum of a light source, while glucose or a similarly absorbing material can be embedded in an optical potting material or the like to create a similarly tuned filter for a corresponding optical sensor. The supporting hardware may usefully be deployed in a wearable physiological monitor for continuous monitoring of glucose (or other target molecules) in the tissue of a user.

WEARABLE DUAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS FOR PRECISION DIABETES MANAGEMENT

Resumen de: US20260199601A1

0000 A wearable dual closed-loop insulin delivery system is provided that integrates both a chemical closed-loop and an electronic closed-loop for precise glycemic control. The system includes a continuous glucose monitor (CGM) configured to obtain real-time blood glucose concentrations of a subject, and a glucose-responsive insulin (GRI) delivery device containing a GRI formulation that autonomously modulates its insulin-release rate in response to the subject's glucose levels, thereby forming a chemical closed-loop. The system further includes a controller having one or more computer processors executing a machine-learning adaptive glucose forecasting model with an Encoder-Decoder architecture. The model receives real-time glucose measurements from the CGM, predicts glycemia dynamics for at least a time period (i.e., 30 minute) future interval, and generates dosing-control signals to adjust both insulin-dosing amount and timing, forming an electronic closed-loop. The controller is operatively connected to the CGM and the GRI delivery device, enabling predictive, automated insulin regulation.

INSULIN PEN-TYPE SYRINGE REFRIGERATION CUP

Resumen de: US20260199610A1

0000 An insulin pen-type syringe refrigeration cup is provided, which is provided with an insulin pen cartridge. The insulin pen-type syringe refrigeration cup includes a refrigeration component, a cold conduction tube, a cup lid, and a cup body. The cold conduction tube defines a storage space that accommodates insulin pens, the storage space is also suitable for accommodating the insulin pen cartridge. A diameter of the cold conduction tube is 20 mm-50 mm. The cold conduction tube includes an avoidance groove. The cup lid is suitable for accommodating the refrigeration component. The cup body includes a cup wall and an insulation chamber. The cup lid can detachably seal the insulation chamber, and the refrigeration component keeps the insulation chamber in a low temperature state. The present disclosure significantly reduces the volume by limiting the size of the cold conduction tube and providing the avoidance groove.

GLUCOSE LEVEL INDICATOR MODEL WITH MODIFIED ERROR RATE

Resumen de: US20260198867A1

A system is described herein comprising at least one application running on one or more processors of a server, wherein the at least one application is communicatively coupled with one or more sensor devices and a remote mobile device, the one or more sensor devices configured to monitor real time biometric data of a subject, the one or more sensing devices configured to transmit the real time biometric data to the at least one application, the at least one application configured to extract feature data variables from the real time biometric data, apply a predictive model to the feature data variables to predict glucose levels of the subject over a future period of time, and communicate a signal to the mobile device when predicted glucose levels cross either an upper or lower threshold.

METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS

Nº publicación: WO2026151664A1 16/07/2026

Solicitante:

SANA BIOTECHNOLOGY INC [US]
SANA BIOTECHNOLOGY, INC.

Resumen de: WO2026151664A1

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and/or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).